, consistent with BY's manganese sensitivity.
Pmr1 leucine-548 is conserved across fungi, with some species having an isoleucine or valine at the homologous position and none with phenylalanine ( fig. S5 ). In the S. cerevisiae population, almost all sequenced PMR1 alleles have leucine-548, with phenylalanine-548 found only in BY and other laboratory strains (12, 13) whose PMR1 alleles are likely directly related to BY (14) . BY is derived from EM93, a diploid strain isolated from a fig (15) . Sequencing of PMR1 in EM93 revealed that EM93 is heterozygous for Pmr1-F548L ( fig. S6 ), suggesting that either the mutation is not laboratory-derived or that it occurred between EM93's isolation and its entry into a stock collection.
Decades of mapping studies have uncovered loci for myriad traits, but identification of the underlying genes and variants has lagged. Our CRISPR-assisted mapping approach promises to close this gap. In contrast to previous strategies, our method generates a higher density of recombination events, is easily targetable to any region of the genome, and does not require time-consuming extra generations of crossing to increase recombination frequency. Conversely, the strength of a traditional meiotic mapping panel is the ability to scan the entire genome. Complex traits, with multiple small-effect QTLs, pose a greater challenge for any mapping method. Importantly, in LOH mapping the rest of the genome outside the region targeted for LOH is held constant when a given QTL is being queried, thus effectively reducing the complexity of a trait by eliminating variance due to other segregating QTLs.
We anticipate that trait mapping with targeted LOH panels will aid efforts to understand the genetic basis of trait variation. In addition to applications in single-celled organisms, LOH panels could be generated from cultured cells, enabling in vitro genetic dissection of human traits with cellular phenotypes. In multicellular organisms, mapping resolution could be enhanced with CRISPR-directed meiotic recombination events. Indeed, the mutagenic chain reaction system developed in vivo in fruit flies (16) and mosquitos (17, 18) uses CRISPR to generate gene conversion events in meiosis with high efficiency. Additionally, LOH in early development could generate chimeric individuals. The targeted LOH method also has the potential to be applied to viable interspecies hybrids that cannot produce offspring, allowing trait variation between species to be studied genetically beyond the few systems where it is currently possible (19, 20) .
In addition to their research applications, targetable endonucleases hold promise for gene therapy (21, 22) . Certain disease alleles may be difficult to directly target by CRISPR because of their sequence complexity, such as the expanded trinucleotide repeats that underlie Huntington's disease. In these cases, directing a DSB to occur in the vicinity of a pathogenic allele so that it is replaced with its nonpathogenic counterpart by LOH may represent a more feasible alternative. 
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ntestinal microbiota modulate development and function of the immune system and play a critical role in inflammatory bowel disease (IBD), a family of idiopathic intestinal disorders including Crohn's disease (CD) and ulcerative colitis (UC) (1) (2) (3) (4) (5) (6) . Concordance rates of 40 to 50% between monozygotic twins implicate gene-environment interactions in the pathogenesis of CD (7) (8) (9) (10) , albeit in ways that are poorly understood. Advances in DNA-sequencing technologies have empowered unprecedented insights into the human genome and the gut microbiome in IBD, enabling detailed genomic characterization of patients (11) and chronicling alterations in the composition and gene content of the gut microbiome (dysbiosis) (12) .
Close to 200 risk loci have been proposed for CD, with several susceptibility genes linked to the regulation of autophagy (e.g., autophagyrelated 16-like 1, ATG16L1) (13) (14) (15) or to microbial sensors that activate autophagy [e.g., nucleotidebinding oligomerization domain-containing protein 2 (NOD2)] (16) (17) (18) . Although previous studies have shown that disruption of ATG16L1 and NOD2 affects CD susceptibility through defects in microbial clearance (19) (20) (21) (22) (23) , recent reports reveal that immune cells impaired in autophagy are hyperinflammatory (24) (25) (26) (27) (28) (29) . This suggests that deficiencies in ATG16L1 or NOD2 may contribute to CD risk through impaired anti-inflammatory responses, a hypothesis not mutually exclusive with microbial clearance functions.
The microbiome of CD patients is altered, with emerging evidence for cause-and-effect relationships to disease. Among other recent examples of host-microbe interactions (3, 5, 6) , the human commensal Bacteroides fragilis has evolved beneficial immunomodulatory properties. During colonization of mice, B. fragilis capsular polysaccharide A (PSA) is packaged in outer membrane vesicles (OMVs) and delivered to intestinal dendritic cells (DCs) to induce interleukin-10 (IL-10) production from CD4 + Foxp3
+ regulatory T cells (T regs ), which protects from experimental colitis (30) (31) (32) . To explore gene-environment interactions during host-microbiota symbiosis, we tested if genetic pathways linked to CD are involved in the immune response to B. fragilis OMVs.
Bone marrow-derived DCs (BMDCs) differentiated from wild-type (WT) and ATG16L1-deficient (Atg16l1 f l/f l Cd11c-Cre; Atg16l1
DCd11c
) mice were pulsed with OMVs harvested from wild-type B. fragilis (WT-OMV), or an isogenic mutant lacking PSA (DPSA-OMV), and cocultured with CD4 + T cells. As previously reported (33), WT-OMVs, but not vehicle or DPSA-OMVs, promote IL-10 production ( Fig. 1 , A to C, and fig. S1 ). Conversely, ATG16L1-deficient DCs do not support IL-10 production in response to WT-OMVs (Fig. 1 , A to C). We observe similar results using Atg16l1 fl/fl LysM-Cre mice ( fig. S3 ). Purified PSA does not require ATG16L1 for its activity (Fig. 1 , A and C, and fig. S2 ). Next, we tested functional outcomes using in vitro T cell suppression assays. T regs isolated from cocultures with Atg16l1
DCd11c BMDCs treated with B. fragilis OMVs exhibit impaired suppressive activity (Fig. 1D and fig. S2A (Fig. 1F) . As RUBICON is upstream of ATG16L1 signaling, OMVs preferentially use the noncanonical autophagy pathway LAP to mediate tolerogenic responses to B. fragilis. Further, these data suggest a reconsideration of previous literature assigning the role of ATG16L1 in IBD to defects exclusively in autophagy.
As a CD-risk gene, we investigated the in vivo requirement for ATG16L1 in CD11c + DCs during OMV-mediated protection from experimental colitis. Indeed, WT mice treated by oral gavage with WTOMVs are protected from 2,4-dinitrobenzenesulfonic acid (DNBS) colitis (33), whereas Atg16l1 DCd11c mice exhibit acute weight loss and increased mortality similar to that of untreated mice ( Fig. 2A and fig.  S8A ). WT, but not Atg16l1
, mice orally administered OMVs are protected from shortening of the colon, a hallmark of colitis models (Fig. 2B) , with colitis scoring and cytokine profiles verifying protection from disease ( Fig. 2C and fig. S8B ). Prevention of colitis is not due to an overall defect in T reg development in Atg16l1 T regs compared to WT mice after WT-OMV treatment ( Fig. 2D and fig. S8C ). Thus, WT-OMVs require ATG16L1 within DCs to induce IL-10 expression from Foxp3 + T regs and to suppress intestinal inflammation in a colitis model.
In addition to impaired IL-10 production in response to OMV treatment, Atg16l1
DCd11c mice display an increase in IL-17A expression (Fig. 2E) S15 ). These data are consistent with previous reports of a hyperinflammatory response in ATG16L1-deficient macrophages and DCs stimulated with other microbial ligands (24, 26) . Abrogation of T reg responses by ATG16L1-deficient DCs is likely due to increased proinflammatory cytokine production, which may impair DC-T cell interactions. Atg16l1 DCd11c mice do not display more severe colitis than WT mice in the absence of OMV treatment (Fig. 2) , suggesting that lack of protection is not due to more fulminant inflammation, but rather to an inability to induce T regs in mice deficient in ATG16L1 among CD11c + DCs. NOD2 encodes an intracellular sensor of bacterial peptidoglycan, and polymorphisms in this gene contribute to the largest fraction of genetic risk for CD (13) . NOD2 has been shown to physically recruit ATG16L1 (20, 21) , a process that is impaired in human cells homozygous for a NOD2 frameshift mutation (20) . Accordingly, Nod2 −/− BMDCs pulsed with WT-OMVs are unable to support IL-10 production from Foxp3 + T regs during in vitro cocultures (Fig. 3, A and B) , revealing a crucial role for NOD2 signaling in microbiome-mediated immune tolerance. This notion is supported by in vivo studies showing that Nod2 −/− mice are not protected from colitis by WT-OMV treatment (Fig. 3, C and D) . Similar to Atg16l1 DCd11c animals, Nod2 −/− mice produce significantly less IL-10 from Foxp3 + T regs of the mesenteric lymph node (MLN) after WT-OMV treatment ( fig. S16A ), and proportions of T regs remain unchanged during DNBS colitis ( fig. S16B) . Previous studies have shown that Toll-like receptor 2 (TLR2) is required for the PSA response (33, 37) . Although the role of NOD2 in inducing LAP is currently unknown, signaling through TLR2 potently activates LAP (36, 38) . B. fragilis OMVs induce reactive oxygen species from WT DCs, Error bars represent SEM. *P < 0.05, ***P < 0.001, ****P < 0.0001. Twoway ANOVA, followed by Tukey's post-hoc analysis. Data are representative of at least three independent experiments, with three to nine mice per group.
a known product of LAP activation (36) , but at significantly reduced levels in Nod2 −/− or Tlr2 −/− DCs ( fig. S17 ). Though further studies are needed to define the mechanism of LAP activation by OMVs, these data reveal that NOD2 and ATG16L1 may cooperate as part of a common pathway to promote anti-inflammatory immune responses to the microbiome. To extend and validate gene deletion approaches, we tested responses to OMVs by immune cells carrying the CD-associated variant of ATG16L1 (13, 14, 39) . The ATG16L1 T300A variant leads to protein instability and altered cellular responses (23) . BMDCs from transgenic mice expressing the T300A allele are also unable to promote IL-10 expression from Foxp3 + T regs in response to WTOMVs ( fig. S18A) . Further, ATG16L1 T300A transgenic mice are not protected from DNBS colitis and do not mount a potent T reg response when administered WT-OMV compared to WT mice ( fig. S18 , B to G). These findings prompted us to investigate if human immune cells from CD patients with the ATG16L1 T300A risk variant (table S1) are also defective in promoting Foxp3 + T reg development by B. fragilis OMVs. Monocytederived dendritic cells (MoDCs) from CD patients and healthy controls harboring either the protective allele (T300) or the risk allele (A300) were pulsed with OMVs or PSA and cocultured with syngeneic CD4 + T cells. Consistent with our mouse data, human cells homozygous for the risk allele are unable to support induction of IL-10 from Foxp3 + T regs by WT-OMVs compared to MoDCs carrying the protective allele (Fig. 4) . Notably, all samples tested display the predicted outcome based on genotype and not disease status. However, cells from most subjects, regardless of genotype, respond to purified PSA (Fig. 4) . Collectively, we conclude that mouse and human DCs require functional ATG16L1 for induction of CD4 IBD affects more than 1.5 million people in the United States, with rates of diagnosis increasing and treatment options remaining limited (40, 41) . The etiology of IBD is complex and incompletely resolved (1) . Here, we describe how interactions between genetic (ATG16L1/NOD2) and environmental (microbiome) factors cooperate to promote beneficial immune responses. B. fragilis OMVs use LAP, an ATG16L1-dependent cellular trafficking and signaling pathway, to induce mucosal tolerance. The hyperinflammatory responses that occur with mutations in ATG16L1 likely alter antigen-processing pathways and impair signaling by DCs to T cells and may explain why CD-associated polymorphisms abrogate T reg induction by OMVs. Collectively, discovery of genetic circuits co-opted by the microbiome to engender health provides unprecedented functional insights into gene-environment interactions relevant to the pathogenesis of IBD. We propose an additional role for genes previously implicated in killing bacteria-namely, mutations in genetic pathways linked to IBD result in an inability to sense and/or respond to beneficial microbes. This hypothesis may represent a new perspective for the etiology of microbiome-related diseases. Human samples were processed and analyzed in a blinded fashion. CTL, control subjects; CD, Crohn's disease subjects. Error bars represent SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant. One-way ANOVA, followed by Tukey's posthoc analysis.
